P anx1 (pannexin 1) channels have emerged as a major means for release of the nucleotides that mediate purinergic signaling, 1 which is involved in multiple physiological and pathophysiological processes such as apoptosis, 2 pyroptosis, 3 tumor cell metastasis, 4 vasoconstriction, 5 leukocyte migration, 6 insulin release from adipocytes, 7 N-methyl-D-aspartate receptor activation, 8 and neuronal survival. 9 Of particular relevance to this current work, Panx1 channels are activated by both caspase-dependent cleavage of the carboxyl terminus and cleavage-independent, receptor-mediated activation mechanisms. During apoptosis, caspase 3/7 cleaves the carboxyl terminus of Panx1, resulting in an irreversibly activated channel that can release ATP as a find-me signal to surrounding phagocytes.
P anx1 (pannexin 1) channels have emerged as a major means for release of the nucleotides that mediate purinergic signaling, 1 which is involved in multiple physiological and pathophysiological processes such as apoptosis, 2 pyroptosis, 3 tumor cell metastasis, 4 vasoconstriction, 5 leukocyte migration, 6 insulin release from adipocytes, 7 N-methyl-D-aspartate receptor activation, 8 and neuronal survival. 9 Of particular relevance to this current work, Panx1 channels are activated by both caspase-dependent cleavage of the carboxyl terminus and cleavage-independent, receptor-mediated activation mechanisms. During apoptosis, caspase 3/7 cleaves the carboxyl terminus of Panx1, resulting in an irreversibly activated channel that can release ATP as a find-me signal to surrounding phagocytes. 2 Alternatively, Panx1 channels, which are also expressed in smooth muscle cells (SMCs), are reversibly activated in a receptor-dependent mechanism. In vascular SMCs, we and others have demonstrated that sympathetic-mediated vasoconstriction and blood pressure are Panx1 dependent based on genetic and pharmacological perturbation. 5, [10] [11] [12] [13] Specifically, activation of α1-adrenergic receptors results in opening of Panx1 channels that activate downstream purinergic receptors through release of ATP. Small ions and large molecules can permeate through open Panx1 channels, which allows for Panx1 channel activities to be assayed in several ways: by entry into cells of dyes, such as TO-PRO-3 or ethidium bromide; by release of nucleotides, such as ATP and UTP (uridine triphosphate); and by plasma membrane Panx1 channel currents (reviewed in [14] [15] [16] ). Given the paucity of selective compounds capable of targeting Panx1, we used different assays to identify and validate new Panx1 blockers that would be useful in these various pathophysiological contexts, such as treatmentresistant hypertension.
Here, using an unbiased screen for small molecules 17 targeting Panx1, we identify spironolactone as a potent inhibitor of Panx1. Spironolactone is an effective antihypertensive drug and is considered by the World Health Organization as an essential medication to be held by all countries. Interestingly, the addition of spironolactone is beneficial to patients already prescribed 3 drugs from different classes, including a diuretic, and thus, the blood pressure reduction action of spironolactone could be partially attributed to off-target effects. 18, 19 Because Panx1 can regulate α1-adrenergic receptor-mediated vasoconstriction and blood pressure, 5 we assessed whether Panx1 may contribute to the antihypertensive effects of spironolactone as an off-target effect. The data presented herein indicate that Panx1 is a novel target of spironolactone and potential therapeutic target for patients with resistant hypertension.
Methods
Detailed experimental methods are available in Methods in the Online Data Supplement.
The data that support the findings of this study are available from the corresponding author on reasonable request.
Results
We previously detailed a medium-throughput flow cytometrybased assay, based on TO-PRO-3 dye uptake into Jurkat T cells that are induced to undergo Fas-mediated apoptosis, as a measure for PANX1 channel activity. 17 By screening a Library of Pharmacologically Active Compounds library of small molecules using this assay, we now identify spironolactone as a PANX1 inhibitor. In validation studies, in a dose-dependent fashion, spironolactone blocked both PANX1-dependent ATP release from apoptotic cells and TO-PRO-3 dye uptake into these cells ( Figure 1A ). Structurally (but not functionally) similar compounds such as aldosterone (or progesterone) failed to inhibit Panx1 channel activity (Online Figure I) .
To test directly the effect of spironolactone on ionic currents through plasma membrane human PANX1 channels, we performed whole-cell recording from anti-Fas-treated Jurkat cells. In these apoptotic cells, spironolactone reversibly inhibited membrane currents with current-voltage properties characteristic of PANX1 channels, reducing currents equally well at both positive and negative potentials ( Figure 1B ). After washing, the current sensitive to spironolactone was fully blocked by carbenoxolone, a drug known to inhibit PANX1. Spironolactone inhibited ≈60% to 80% of the maximal carbenoxolone-sensitive currents ( Figure 1B ). Spironolactone dose dependently inhibited C-terminal cleavage-activated recombinant PANX1 currents in HEK293T cells 20 with an IC 50 of ≈7 to 8 μmol/L ( Figure 1C ), approximately the concentration of spironolactone estimated to be achieved in tissues. 21, 22 We also performed single-channel recordings using the inside-out patch-clamp configuration to test more directly the effects of spironolactone on PANX1 channels in a cellfree system. Addition of spironolactone strongly reduced the amount of time that the channels spent in the open state (open probability, depicted as open probability), suggesting that spironolactone can directly inhibit PANX1 channels at the plasma membrane, without requiring other cytoplasmic or nuclear factors ( Figure 1D 
Novelty and Significance
What Is Known?
• Spironolactone is a widely used mineralocorticoid receptor inhibitor and effective antihypertensive drug, particularly for treatment-resistant hypertensive patients.
• Off-target effects of spironolactone have been thought to also contribute to its effectiveness in treatment-resistant hypertensive patients. • Panx1 (pannexin 1), a nucleotide-release channel, has been shown to regulate various physiological processes, including receptor-mediated vasoconstriction.
What New Information Does This Article Contribute?
• Spironolactone is a potent inhibitor of Panx1 channels.
• α-adrenergic receptor-mediated vasoconstriction of arterioles from treatment-resistant hypertensive patients is inhibited by spironolactone.
• Spironolactone acutely reduces blood pressure in mice, an effect independent of the mineralocorticoid receptor, but requires Panx1 in smooth muscle cells.
Treatment-resistant hypertension is a major problem around the world that can be ameliorated by spironolactone, a drug class that is often used as key second line of treatment. Although the primary action of spironolactone is linked to the mineralocorticoid receptor, the mechanisms for its efficacy in acute reduction of blood pressure and the various nongenomic effects of spironolactone remain unexplained. First, we detail the unexpected discovery that Panx1 channels are additional, potentially therapeutically relevant, molecular targets of spironolactone. We identified spironolactone as a potent inhibitor of Panx1 in an unbiased small molecule screen. Panx1 has been shown to be important for α-adrenergic vasoconstriction and indeed spironolactone inhibited α-adrenergic vasoconstriction in hypertensive human arterioles and mouse peripheral arterioles. This effect was lost when Panx1 expression was specifically deleted from vascular smooth muscle cells but was fully retained in mice lacking the mineralocorticoid receptor in smooth muscle cells. Likewise, at the whole animal level, spironolactone caused an acute lowering of blood pressure that was dependent on expression of Panx1 in smooth muscle cells, but independent of mineralocorticoid receptor. These data identify Panx1 as a novel target of spironolactone and suggest the potential for new therapeutic modalities for treatment-resistant hypertension based on Panx1 channel inhibition. average open probability of PANX1 channels by 3-to 4-fold (at −60 mV, from 2.4±0.7 to 0.8±0.2; at +60 mV, from 2.0±0.5 to 0.5±0.9 [ Figure 1E ], without affecting channel conductance [ Figure 1F ]). These data suggest that PANX1 is a new and previously unappreciated target of spironolactone, which inhibits the channel at concentrations that are achievable in patients. Spironolactone is an effective antihypertensive drug, especially used in patients with hypertension that is resistant to the first line of therapies. Thus, we examined human arterioles isolated from resistant hypertensive individuals by immunohistochemistry and found that PANX1 channels were expressed in vascular SMCs, where α-smooth muscle actin is also localized, and endothelial cells ( Figure 1G ). Because spironolactone can be an effective treatment for high blood pressure in resistant hypertensive humans, 18 and because Panx1 channels are involved in regulating α1-adrenergic arteriolar vasoconstriction and blood pressure in mice, 5 we tested whether spironolactone affects α1-adrenergic vasoconstriction in PANX1-expressing vessels from patients with resistant hypertension. Isolated, pressurized resistant hypertensive human arterioles were stimulated with an α1-adrenergic receptor agonist, phenylephrine, with or without spironolactone treatment. In parallel experiments, we used a membrane-permeable peptide denoted PxIL2P (Panx1 intracellular loop 2 peptide) that we previously developed to inhibit PANX1-dependent, α1-adrenergic receptor-mediated vasoconstriction. 5 Arterioles from resistant hypertensive humans constricted in response to phenylephrine, and both spironolactone and PxIL2P inhibited phenylephrine-induced vasoconstriction in these isolated human arterioles ( Figure 1H ).
We next tested the effect of spironolactone on recombinant Panx1 currents induced by α1-adrenergic receptor activation and found robust inhibition of both mouse and human PANX1 channels ( Figure 2A ; Online Figure IIA and IIB). We then tested whether spironolactone inhibited Panx1-mediated α1-adrenergic vasoconstriction using resistance arteries from mice. 23 Thoracodorsal arteries were first treated with increasing concentrations of phenylephrine in the presence of a maximum dose of spironolactone (80 μmol/L), which resulted in blunted vasoconstriction ( Figure 2B ). The effect of spironolactone on the arteries was reversible, as washing out the spironolactone and treating the same arteries with phenylephrine alone showed a typically strong vasoconstriction (diameter reduced by ≈70%; Figure 2B ). Furthermore, vessel function was not adversely affected by spironolactone or phenylephrine because the arteries dilated fully when treated with acetylcholine, contracted maximally in the presence of potassium chloride, and were again fully dilated after calcium was removed from the bath ( Figure 2B ). To determine an IC 50 for spironolactone action in this assay, we exposed arteries to increasing doses of spironolactone before testing vasoconstrictor actions of increasing concentrations of phenylephrine ( Figure 2C ). Spironolactone inhibited phenylephrine-induced vasoconstriction in a dose-dependent manner. The IC 50 of ≈ 18.9 μmol/L for 1 μmol/L phenylephrine determined using whole arteries is within the range of spironolactone concentrations estimated to be achieved in tissues 21 and was only slightly higher than the IC 50 from in vitro electrophysiology measurements (≈8 μmol/L; Figure 1C ).
Next, we tested whether this effect of spironolactone on phenylephrine-induced vasoconstriction was dependent on Panx1 expression in the endothelium or the smooth muscle. We used mice with floxed Panx1 alleles crossed to transgenic mice that express tamoxifen-inducible CreER ). We previously demonstrated inducible and efficient deletion of Panx1 after tamoxifen injection with these 2 Cre strains. 5, 6 Deletion of Panx1 specifically from endothelial cells in the Panx1 fl/fl /ECCreER T2+ mice did not affect the ability of spironolactone to inhibit α1-adrenergic vasoconstriction ( Figure 2D ). littermates injected with vehicle alone (without tamoxifen), phenylephrine-induced vasoconstriction and inhibition of vasoconstriction by spironolactone was preserved ( Figure 2F ). Notably, there were no differences in the endothelial-dependent arterial dilation with acetylcholine among all tested mice (Online Figure IIC) . Importantly, vasoconstriction induced by serotonin, which is independent of Panx1 channels, 5 was comparable in mice lacking Panx1 in vascular SMCs, endothelial cells, and control mice (Online Figure IID) . These data suggest that Panx1 expression, specifically in the vascular SMCs, is a key requirement for spironolactone to inhibit α1-adrenergic receptor-mediated vasoconstriction of resistance arteries. This is an important distinction from large conduit arteries (eg, aorta) that do not directly regulate blood pressure, Representative inside-out patch recording from HEK293T cell coexpressing PANX1(TEV) and TEV protease before (left) and after (right) spironolactone (20 μmol/L) application, at patch potentials of +60 mV (upper) or −60 mV (lower). The traces on the right are shown to depict data indicating that majority of the channels are in the closed state (C) after spironolactone addition compared with control conditions. E, Open probability (NPo) of PANX1 channels was reduced by spironolactone (20 μmol/L, n=7). **P<0.01 by 2-tailed paired t test. F, Unitary conductance of PANX1 channels was unaffected by spironolactone (20 μmol/L, n=7). Unitary conductance (mean±SEM) are 91.0±1.5 pS (control) and 89.5±1.7 pS (spironolactone) at patch potentials between +50 mV and +80 mV, and 13.5±1.9 pS (control) or 11.5±1.5 pS (spironolactone) at patch potentials between −70 mV and −50 mV, respectively. G, Arterioles from human patients with resistant hypertension showed expression for PANX1 (magenta) that were not seen when secondary antibodies alone (IgG) were used. A, Exemplar whole-cell recording from an HEK293T cell coexpressing mouse Panx1 channels and α1D adrenergic receptors. Phenylephrineinduced currents (cyan shading) are inhibited by spironolactone (20 μmol/L; green shading) and further by carbenoxolone (CBX; 50 μmol/L; red shading). Inset: whole-cell current at +80 mV during sequential application of phenylephrine, spironolactone, and CBX (in the continued presence of phenylephrine). B, Representative trace of phenylephrine-induced vasoconstriction of a C57Bl/6 thoracodorsal artery. Vasoconstriction was blunted when 80 μmol/L spironolactone was present; after washing off the spironolactone, the thoracodorsal artery regained the ability to contract in response to phenylephrine. To confirm vessel integrity was not affected the spironolactone treatment, 10 μmol/L acetylcholine (ACh) was used for vasodilation, and 40 mmol/L KCl was used for inducing vasoconstriction, followed by maximal dilation achieved via a Ca 2+ -free solution. C, Control vessels from C57Bl/6 mice treated with dimethyl sulfoxide (DMSO) vehicle control (N=6 mice, n=6 vessels) or 10 (N=4 mice, n=4 vessels), 20 (N=5 mice, n=5 vessels), 40 (N=5 mice, n=5 vessels), or 80 (N=5 mice, n=5 vessels) μmol/L spironolactone show dose-dependent inhibition of phenylephrine-induced vasoconstriction. Repeated measures 2-way ANOVA showed significant differences between DMSO vehicle control vs 20, 40, or 80 μmol/L spironolactone at 10 −6 to 10 −3 mol/L phenylephrine. Inset: IC 50 for spironolactone was determined to be ≈ 18.9 μmol/L at 1 μmol/L phenylephrine (10 −6 mol/L). D, Endothelial cell deletion of Panx1 retained significant reduction of phenylephrine-induced vasoconstriction on treatment with 80 μmol/L spironolactone. DMSO vehicle control: N=4 mice; n=6 vessels; spironolactone: N=4; n=7. Repeated measures 2-way ANOVA showed significant differences between DMSO vehicle control vs 80 μmol/L spironolactone at 10 −6 to 10 −3 mol/L phenylephrine. E, F, Smooth muscle cell deletion of Panx1 after tamoxifen injection (E) prevented the inhibitory effect of 80 μmol/L spironolactone on phenylephrine-induced vasoconstriction, whereas this was retained in Panx1 fl/fl /SMC-CreER T2+ mice injected with the control vehicle (peanut oil; F). Tamoxifen-injected mice: DMSO vehicle control N=6 mice, n=11 vessels; spironolactone treated N=5 mice, n=10 vessels. Vehicle injected: DMSO vehicle control N=6 mice, n=11 vessles; spironolactone treated N=6 mice, n=9 vessels. Two-way ANOVA and significant differences at any dose of phenylephrine are shown. For all graphs: mean±SEM and *P<0.05. EC indicates endothelial cell; and SMC, smooth muscle cell. do not express Panx1 in SMCs, 24 and have α1-adrenergic responses that are not inhibited by spironolactone. 25 Endothelial Panx1 in conduit arteries has been suggested to regulate vascular tone 26 ; however, we find no effect of Panx1 deletion from endothelial cells on phenylephrine-induced vasoconstriction or acetylcholine-induced vasodilation, further supporting the concept that resistance arteries and conduit arteries use different mechanisms for sympathetic regulation of vascular tone.
It is well established that spironolactone is an antagonist of the mineralocorticoid receptor (MR) NR3C2, acting in the kidney and vascular SMCs to lower blood pressure. [27] [28] [29] [30] However, rapid, nongenomic, and seemingly MR-independent off-target effects of spironolactone have been reported as contributing to its larger beneficial antihypertensive actions. [31] [32] [33] [34] [35] These non-MR effects have largely remained unexplained. Therefore, we examined whether the inhibitory effect of spironolactone on α1-adrenergic, Panx1-dependent vasoconstriction required the MR, NR3C2. We tested this via 4 different means. First, we used NR3C2 siRNA to knockdown NR3C2 expression in Jurkat cells and tested TO-PRO-3 uptake after induction of apoptosis. TO-PRO-3 uptake occurred comparably in control and NR3C2 knockdown cells and was inhibited equally by spironolactone ( Figure 3A ; Online Figure IIIA) . Second, we crossed mice carrying floxed alleles of Nr3c2 with SMC-CreER T2+ mice, and after tamoxifen injection to induce Nr3c2 deletion (SMC Nr3c2-knockout [KO]), we assessed spironolactone effects on α1-adrenergic vasoconstriction. In arteries from tamoxifen-treated Nr3c2 fl/fl /SMC-CreER T2+ mice, spironolactone was still able to blunt vasoconstriction induced by phenylephrine ( Figure 3B ). We confirmed that Nr3c2 was indeed deleted in thoracodorsal arteries after tamoxifen injection (Online Figure IIIB) and that these thoracodorsal arteries were fully responsive to Panx1-independent vasodilation or vasoconstriction (Online Figure IIIC) . Third, we tested the effect of spironolactone on phenylephrine-induced uptake of TO-PRO-3 into arteries from C57Bl/6 control mice, smooth muscle Nr3c2-deleted (SMC Nr3c2-KO) mice, or smooth muscle Panx1-deleted (SMC Panx1-KO) mice ( Figure 3C ). Similar to control vessels, thoracodorsal arteries lacking Nr3c2 retained the ability to take up TO-PRO-3 in response to phenylephrine, and this dye uptake was abolished by spironolactone. This phenylephrine-induced dye uptake was dependent on Panx1, as it was not observed in arteries lacking Panx1 in the vascular SMCs. Together these data indicate that the spironolactone-mediated inhibition of α1-adrenergic signaling in these assays occurs independent of the MR.
We next asked whether the blood pressure changes induced by spironolactone administration in vivo relate to Panx1. For this, we focused on the short-term/acute, nongenomic effects of spironolactone on blood pressure expected from Panx1 regulation of sympathetic vascular responses, recognizing that it would be difficult to distinguish those from other MR-dependent genomic changes on BP under longerterm treatment conditions. Spironolactone evoked a rapid decrease in mean arterial pressure (MAP) when injected into C57Bl/6 control and SMC Nr3c2-KO, whereas spironolactone did not reduce blood pressure in SMC Panx1-KO mice or mice with global deletion of Panx1 (Panx1 −/−17 ; Figure 3D and 3E; Online Figure IIIE and IIIH) . We also tested the effect of spironolactone on spontaneously hypertensive BPH/2 mice, with elevated MAP that is largely attributed to sympathetic overdrive. 36 In these BPH/2 mice, again, spironolactone induced a strong reduction in MAP.
We also used additional pharmacological agents to differentiate effects mediated by Panx1 and the MR. Recently, nonsteroidal MR antagonists, such as finerenone, have been developed to overcome the side effects of spironolactone that causes it to be discontinued during long-term treatments (primarily because of spironolactone acting as a partial progesterone receptor agonist and causing gynecomastia). Finerenone did not affect PANX1 currents ( Figure 3E ) and did not reduce MAP in any of these groups of mice, producing effects similar to vehicle injection (dimethyl sulfoxide; Figure 3E ; Online Figure IIIF) . We also tested trovafloxacin, a distinct small molecule Panx1 inhibitor previously identified in a screen 17 ; injection of trovafloxacin caused a decrease in MAP in C57Bl/6 control, SMC Nr3c2-KO, and BPH/2 hypertensive mice, whereas it had no effect in mice lacking Panx1 in the vascular SMCs (SMC Panx1-KO mice, Online Figure  IIIG and IIII). We further verified our earlier results that SMC Panx1-KO mice have reduced blood pressure, which is most pronounced at night when sympathetic activity is typically highest, 5 and we confirmed that the BPH/2 hypertensive mice also had significantly higher MAP (Online Figure IIID) . Collectively, these in vitro and in vivo data indicate that spironolactone can act via Panx1 channels to acutely lower blood pressure, independently of the MR NR3C2.
In vivo, spironolactone is converted to metabolites including canrenone (sold as an antihypertensive drug) and 7-α-thiomethylspirolactone. 37 In addition, the spironolactonederived compound eplerenone is a steroidal MR antagonist that is more MR specific, but less potent than spironolactone, and also used clinically. 38 We found a dose-dependent decrease in PANX1-dependent TO-PRO-3 uptake by anti-Fas-treated, apoptotic Jurkat cells exposed to canrenone and eplerenone ( Figure 4A ; Online Figure IVA) , and again both of these effects were independent of NR3C2 ( Figure 4A ). Canrenone and eplerenone also inhibited ATP release in a dose-dependent fashion (Online Figure IVB) . Likewise, and similar to spironolactone, canrenone and 7-α-thiomethylspirolactone inhibited PANX1 currents at hyperpolarized (−50 mV) and depolarized (+80 mV) membrane potentials ( Figure 4B ). Of note, eplerenone also inhibited PANX1 currents at concentrations similar to those achieved in vivo, but was less effective than spironolactone in inhibiting Panx1 in all of the above assays (Figure 4A and 4B; Online Figure IV) . 39 To determine the specificity of these compounds for Panx1 over other topologically related channels, 40 we tested their effects on currents of Panx2 (pannexin 2) channels or Cx43 (connexin 43) hemichannels by using whole-cell recordings. We found that spironolactone, canrenone, or eplerenone did not inhibit recombinant Panx2 or Cx43 currents in HEK293T cells ( Figure 4C and 4D) . These data suggest that spironolactone, as well as its metabolites and analogs, can all inhibit Panx1 channels.
Discussion
Collectively, these studies progress from small molecule screen through target validation to whole animal and human vessel studies to demonstrate that SMC Panx1 channels are an unexpected and potentially functionally relevant target for the effects of spironolactone in α1-adrenergic vasoconstriction and blood pressure regulation. The implications for this discovery are significant for several reasons. First, hypertension is a major driver of cardiovascular risk affecting 40% of adults worldwide, yet roughly half of the hypertensives are not controlled with current therapy; those with this resistant hypertension often respond well to MR antagonist treatment, such as spironolactone. 18, 19 The data presented here on the effect of spironolactone in acutely lowering blood pressure through its effects on Panx1 in the resistance arteries are broadly relevant to understanding mechanisms of resistant hypertension and to the benefits of compounds typically associated with MR antagonism. Indeed, the inhibitory effects of spironolactone on Panx1-mediated α1-adrenergic vasoconstriction in mice and resistant hypertensive humans provide an explanation for prior observations suggesting inhibition of adrenergic responses after spironolactone administration in animals and in humans. 25, 41, 42 Although Panx1 channels are expressed in various types of cells, such as SMCs, 5 endothelial cells, 6 leukocytes, 2 and adipocytes, 7 spironolactone inhibition of α1-adrenergic vasoconstriction and reduction of blood pressure were abolished by deletion of Panx1 specifically in SMCs. Importantly, blood pressure was reduced in normotensive and hypertensive mice, in a vascular smooth muscle Panx1-dependent manner by treatment with spironolactone. These effects seem to be specific to steroidal MR antagonists because the nonsteroidal MR antagonist finerenone did not inhibit PANX1 or acutely reduce blood pressure. A comprehensive evaluation of the specific structural features within steroid or steroid-like compounds that enable Panx1 channel inhibition (eg, spironolactone and derivatives, carbenoxolone) versus those that do not affect Panx1 function (eg, aldosterone, progesterone) awaits further study. We note that both spironolactone and carbenoxolone 13 inhibit PANX1 channels in cell-free patches, suggesting direct effects of these steroidal compounds on channel function. In addition, we were only able to use male mice in this study because the SMMHC-CreER T2+ cre recombinase is located on the Y chromosome 43 leaving open the possibility of sex differences in Panx1-dependent antihypertensive effects of spironolactone. Second, pannexin channels mediate a variety of clinically significant physiological processes, 2,3,5-9 and we have now identified spironolactone as a potent Panx1 inhibitor that can be used to explore further the role and therapeutic potential of Panx1. Third, although spironolactone is an effective antihypertensive, it has side effects limiting its use (eg, particularly hyperkalemia, because of its potassium-sparing actions in the kidney); thus, identification of novel inhibitors targeting Panx1 channels in vivo could be relevant for lowering of blood pressure in such individuals. Finally, beneficial MR-independent effects of spironolactone and related compounds have been widely reported, but remain poorly understood (eg, in heart failure) [31] [32] [33] [34] [35] ; the unexpected discovery of Panx1 as an alternative target for this class of drugs suggests additional possible mechanism worthy of further analysis for those elusive actions.
